Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Press release covers quarter ended September 30, 2026 financial results.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers quarter ended September 30, 2026 financial results
- Corporate update may include pipeline, clinical, or operational developments relevant to valuation
- Exhibit 99.1 contains the substantive results and company disclosures
Item 5.02 · Departure/Election of Directors or Officers
- Derek DiRocco, Ph.D. resigning as director effective December 31, 2026
- Departure not attributed to disagreements with Mineralys or management
- Board composition change, with potential implications for governance and director replacement planning
Item EX-99.1 · Exhibit EX-99.1
- FDA PDUFA target remains December 22, 2026, making approval timing the key near-term catalyst for lorundrostat
- Launch-HTN: 46% on 50 mg reached systolic BP below 130 mmHg at Week 12
- CKD analysis: 52% albuminuria reduction versus placebo, with consistent blood-pressure effects across CKD Stages 1-3
- Commercial spending accelerated, with G&A rising to $37.4 million and net loss widening to $57.3 million
- Cash, cash equivalents and investments totaled $624.7 million, with funding expected through 2028 including commercial launch preparations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.